Hegg, R. (2016) “ A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients ”, Clinics, 71(10), pp. 586–592. doi:10.6061/clinics/2016(10)06.